News | July 09, 2009

Economy Forces European Institutions to Select Lower-Priced Interventional Cardiology Devices

July 9, 2009 – According to Millennium Research Group (MRG), the ongoing economic crisis is putting pressure on publicly funded European healthcare systems, intensifying the decline of interventional cardiology device prices in the region.

MRG's “European Markets for Interventional Cardiology Devices 2009 (Part II)” report details the extent to which competitive pricing and discounts among interventional cardiology device vendors is resulting in price erosion in Belgium, Luxembourg, the Netherlands, Norway, Denmark, Finland, Sweden, Spain and Switzerland.

IC device vendors are engaging in price undercutting and offering high-volume discounts or bundling deals with other products in their portfolios in order to encourage sales, resulting in price erosion. The healthcare systems in the Netherlands and Switzerland (beginning in 2012) provide only general funding for IC procedures, despite the varying cost of devices used. In order to operate within set budgets, European healthcare facilities must often choose lower-cost devices. Contract tenders between sellers and group purchasing organizations will further add to price erosion. In exchange for high-volume sales of their products, manufacturers offer significant discounts. This method of business is becoming more common across Europe, particularly in the Nordic countries and Spain.

MRG's new report provides important insight into the reasons behind and extent of the changes in interventional cardiology device pricing. Additionally, the report provides full breakdowns of procedures by type and device unit sales by subtype, including five-year forecasts, up-to-date market shares and in-depth qualitative insights.

For more information: www.MRG.net

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init